Federal Register / Vol. 74, No. 159 / Wednesday, August 19, 2009 / Notices 41913 

the agreement and proposed order or to 

modify in any way their terms. 

By direction of the Commission. 

Richard C. Donohue 

Acting Secretary. 

[FR Doc. E9–19810 Filed 8–18–09; 1:13 pm] 

BILLING CODE 6750–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–09–0008] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–5960 and 

send comments to Maryam Daneshvar, 

CDC Assistant Reports Clearance 

Officer, 1600 Clifton Road, MS–D74, 

Atlanta, GA 30333 or send an e-mail to 

omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Emergency Epidemic Investigations— 

Extension—(0920–0008), Office of 

Workforce and Career Development 

(OWCD), Centers for Disease Control 

and Prevention (CDC). 

Background & Brief Description 

The purpose of the Emergency 

Epidemic Investigation surveillance is 

to collect data on the conditions 

surrounding and preceding the onset of 

a problem. The data must be collected 

in a timely fashion so that information 

can be used to develop prevention and 

control techniques, to interrupt disease 

transmission, and to help identify the 

cause of an outbreak. The EPI–AID 

mechanism is a means for Epidemic 

Intelligence Service (EIS) officers of the 

Centers for Disease Control and 

Prevention (CDC), along with other CDC 

staff, to provide technical support to 

State health agencies requesting 

assistance with epidemiologic field 

investigations. This mechanism allows 

CDC to respond rapidly to public health 

problems in need of urgent attention, 

thereby providing an important service 

to State and other public health 

agencies. Through EPI–AIDS, EIS 

officers (and, sometimes, other CDC 

trainees) receive supervised training 

while actively participating in 

epidemiologic investigations. EIS is a 

two-year program of training and service 

in applied epidemiology through CDC, 

primarily for persons holding doctoral 

degrees. 

Shortly after completion of the EPI– 

AID investigation, an Epi Trip Report is 

delivered to the State health agency 

official(s) who requested assistance. 

These officials can comment on both the 

timeliness and the practical utility of 

the recommendations from the 

investigation by completing a brief 

questionnaire to assess the promptness 

of the investigation and the usefulness 

of the recommendations. There is no 

cost to the respondents other than their 

time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents 

Number of 

respondents 

(per year) 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Requestors of EPI–AIDs .................................................................................. 100 1 15/60 25 

Dated: August 10, 2009. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E9–19836 Filed 8–18–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

AHRQ Intent To Publish Grant and 

Contract Solicitations for Comparative 

Effectiveness Research (CER) Projects 

With Funds From the American 

Recovery and Reinvestment Act 

(ARRA) 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Notice of Intent. 

SUMMARY: AHRQ is announcing the 

Agency’s intention to support new CER 

projects, with funding from the 

American Recovery and Reinvestment 

Act (ARRA). The ARRA appropriated 

$300 million to AHRQ for support of 

CER. ARRA funding will focus, initially, 

on 14 priority conditions established by 

the Secretary of the Department of 

Health and Human Services under 

Section 1013 of the Medicare 

Prescription Drug, Improvement, and 

Modernization Act of 2003. These 

priority conditions were identified 

through a process involving discussion 

with, and extensive input from, the 

public as well as Federal agencies. The 

list of priority conditions is relevant to 

the Medicare, Medicaid, and State 

Children’s Health Insurance Program 

(SCHIP) programs, and can be found at: 

http://effectivehealthcare.ahrq.gov/ 

aboutUs.cfm?abouttype=program

#Conditions. 

DATES: AHRQ anticipates grant and 

contract solicitations to be published 


jlentini on DSKJ8SOYB1PROD with NOTICES
41914 Federal Register / Vol. 74, No. 159 / Wednesday, August 19, 2009 / Notices 

beginning in the fall, 2009, with funding 

to commence in spring, 2010. Interested 

parties may sign up to receive updates 

about AHRQ’s Effective Health Care 

Program at http:// 

effectivehealthcare.ahrq.gov/. 

ADDRESSES: The future CER solicitations 

will be published in the NIH Guide: 

http://grants.nih.gov/grants/guide/ 

index.html. 

FOR FURTHER INFORMATION CONTACT: 

Until the solicitations are published, 

AHRQ cannot provide information on 

their contents. 

Direct any general comments 

regarding the Effective Health Care 

program to: Lia Hotchkiss, MPH, PMP, 

Center for Outcomes and Evidence, 

Agency for Healthcare Research and 

Quality, 540 Gaither Road, Rockville, 

MD 20850, Telephone: 301–427–1502, 

E-mail address: 

Effectivehealthcare@ahrq.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Background 

The Agency for Healthcare Research 

and Quality (AHRQ) has been 

supporting comparative effectiveness 

research for many years and since 2005 

through AHRQ’s Effective Health Care 

Program, which was authorized under 

Section 1013 of the Medicare 

Prescription Drug, Improvement, and 

Modernization Act of 2003. The 

Effective Health Care program provides 

systematic reviews and develops other 

translational information and tools 

designed to inform health care decision 

making. The Effective Health Care 

Program advances the methodology of 

comparative effectiveness research 

(CER) and provides training grants to 

enhance the pool of researchers who can 

perform CER. 

Comparative Effectiveness Research 

Initiative Description 

Funding Opportunity 

Announcements soliciting research 

grant applications for CER will provide 

$148 million for evidence generation. 

This includes $100 million for the 

Clinical and Health Outcomes Initiative 

in Comparative Effectiveness (CHOICE), 

a new, coordinated, national effort to 

establish a series of prospective 

pragmatic clinical comparative 

effectiveness studies that measure the 

benefits treatments produce in routine 

clinical practice and will include novel 

study designs focusing on real-world 

and under-represented populations 

(children, elderly, racial and ethnic 

minorities, and other understudied 

populations), and $48 million for the 

establishment or enhancement of 

national patient registries that can be 

used for researching the longitudinal 

effects of different interventions and 

collecting data on under-represented 

populations. Additional grant funding is 

expected to include $29.5 million to 

support innovative translation and 

dissemination grants related to CER, as 

well as $20 million to support training 

and career development in CER. 

Requests for Contracts for CER will 

provide $9.5 million to establish an 

infrastructure to identify new and/or 

emerging issues for comparative 

effectiveness review investments. Also, 

$10 million will establish a Citizen’s 

Forum to formally engage all 

stakeholders, and to expand and 

standardize public involvement in the 

entire Effective Health Care enterprise. 

Additionally, AHRQ anticipates 

supporting other grants ($1 million) and 

enhancing existing contracts for 

evidence synthesis ($50 million), 

evidence generation ($24 million), 

translation and dissemination ($5 

million), and salary and benefits for 

ARRA-related full-time equivalent 

positions ($3 million). 

Dated: August 11, 2009. 

Carolyn M. Clancy, 

AHRQ, Director. 

[FR Doc. E9–19758 Filed 8–18–09; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; P01 Application. 

Date: October 28, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: D. G. Patel, PhD, Scientific 

Review Officer, Review Branch, DEA, 

NIDDK, National Institutes of Health, Room 

756, 6707 Democracy Boulevard, Bethesda, 

MD 20892–5452, (301) 594–7682, 

pateldg@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: August 11, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–19889 Filed 8–18–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

Recombinant DNA Advisory Committee. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Recombinant DNA 

Advisory Committee. 

Date: September 9–10, 2009. 

Time: September 9, 2009, 1:15 p.m. to 5:45 

p.m. 

Agenda: The Recombinant DNA Advisory 

Committee will review and discuss selected 

human gene transfer protocols as well as 

related data management activities. Please 

check the meeting agenda at http:// 

oba.od.nih.gov/rdna/rdna.html for more 

information. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Time: September 10, 2009, 8:30 a.m. to 11 

a.m. 

Agenda: The Recombinant DNA Advisory 

Committee will review and discuss selected 

human gene transfer protocols as well as 

related data management activities. Please 

check the meeting agenda at http:// 

oba.od.nih.gov/rdna/rdna.html for more 

information. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Laurie Lewallen, Advisory 

Committee Coordinator, Office of 

Biotechnology Activities, National Institutes 

of Health, 6705 Rockledge Drive, Room 750, 


jlentini on DSKJ8SOYB1PROD with NOTICES